Updates in Oncology
Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities
Pembrolizumab for the treatment of advanced melanoma, under review in Europe
Merck, known as MSD outside the United States and Canada, has announced the European Medicines Agency ( EMA ) has accepted for review a Marketing Authorization Application ( MAA ) for Pembrolizumab ( … read article
Anti-PD-1 and Anti-PD-L1 antibodies
A) Nivolumab
Melanoma: Nivolumab, a PD-1 checkpoint inhibitor, has demonstrated superior overall survival compared to Dacarbazine; Study stopped early
Bristol-Myers Squibb ( BMS ) has announced that a randomized blinded comparative phase 3 study evaluating Nivolumab versus Dacarbazine ( DTIC ) in patients with previously untreated BRAF wild-type adv …
Metastatic renal cell carcinoma: Nivolumab, an anti-PD-1 antibody, in combination with Sunitinib or Pazopanib
Antiangiogenic agents Sunitinib ( Sutent ) and Pazopanib ( Votrient ) are SOC ( standard of care ) for metastatic renal cell carcinoma ( mRCC ), but new therapies are needed as patients advance throug …
B) Pembrolizumab
Melanoma treated with the anti-PD-1 monoclonal antibody Pembrolizumab: clinical efficacy and correlation with tumor PD-L1 expression
Pembrolizumab ( MK-3475 ) has demonstrated antitumor activity and acceptable safety in a phase I melanoma cohort. Researchers have provided updated efficacy data and correlation with tumor PD-L1 exp …
C) Pidilizumab
Safety and efficacy of Pidilizumab, an anti-PD-1 monoclonal antibody, in patients with metastatic melanoma
A phase 2 multicenter, randomized, open-label, study has evaluated the safety and efficacy of Pidilizumab ( CT-011 ), a humanized anti-PD-1 IgG1k, in patients with metastatic melanoma. Eligibility …